Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology
- PMID: 12471186
- DOI: 10.1016/s1051-0443(07)61969-1
Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology
Abstract
Purpose: To evaluate local therapeutic efficacy of radiofrequency (RF) ablation after chemoembolization for hepatocellular carcinoma (HCC) based on tumor size and morphology.
Materials and methods: Sixty-four patients underwent RF ablation under ultrasonographic or real-time computed tomographic (CT) fluoroscopic guidance within 2 weeks after chemoembolization. One hundred eight lesions were treated. Sixty-five lesions were small (<or=3 cm), 32 were intermediate in size (3.1-5 cm), and 11 were large (5.1-12 cm). Seventy-four of the HCCs were nodular lesions and the other 34 were nonnodular (multinodular and infiltrative) lesions. Response to treatment was evaluated by dynamic enhanced CT and magnetic resonance imaging. Tumor necrosis was considered to be complete when no foci of enhancement were seen within the tumor and at its periphery.
Results: Complete necrosis was achieved in all lesions regardless of tumor size or morphology. There have been no local recurrences in small and intermediate-sized lesions regardless of tumor morphology during a mean follow-up of 12.5 months. In large HCCs, nodular lesions showed no recurrence, but two of six of nonnodular lesions recurred beyond the thermal lesions created around the tumor. The estimated 1-year survival rate was 98.0% in all patients.
Conclusions: This combined therapy has a therapeutic effect on small and intermediate-sized HCCs regardless of tumor morphology and is a promising treatment option for large nodular lesions. Control of large nonnodular lesions is still a challenging problem.
Similar articles
-
Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study.J Vasc Interv Radiol. 2009 Dec;20(12):1570-7. doi: 10.1016/j.jvir.2009.09.003. Epub 2009 Oct 30. J Vasc Interv Radiol. 2009. PMID: 19879777
-
Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: Short-term recurrences and survival.Oncol Rep. 2004 Jan;11(1):105-9. Oncol Rep. 2004. PMID: 14654911 Clinical Trial.
-
Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma After Combined Transarterial Chemoembolization and Radiofrequency Ablation.AJR Am J Roentgenol. 2016 Nov;207(5):1122-1127. doi: 10.2214/AJR.16.16080. Epub 2016 Aug 30. AJR Am J Roentgenol. 2016. PMID: 27575338
-
Chemical ablation of hepatocellular carcinoma.J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S245-52. doi: 10.1016/s1051-0443(07)61792-8. J Vasc Interv Radiol. 2002. PMID: 12354842 Review.
-
Combination of ablation and embolization for intermediate-sized liver metastases from colorectal cancer: what can we learn from treating primary liver cancer?Diagn Interv Radiol. 2021 Sep;27(5):677-683. doi: 10.5152/dir.2021.20520. Diagn Interv Radiol. 2021. PMID: 34318754 Free PMC article. Review.
Cited by
-
Biplane fluoroscopy-guided radiofrequency ablation combined with chemoembolisation for hepatocellular carcinoma: initial experience.Br J Radiol. 2011 Aug;84(1004):691-7. doi: 10.1259/bjr/27559204. Br J Radiol. 2011. PMID: 21750136 Free PMC article.
-
Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma.World J Gastroenterol. 2014 Sep 21;20(35):12588-94. doi: 10.3748/wjg.v20.i35.12588. World J Gastroenterol. 2014. PMID: 25253962 Free PMC article.
-
Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC).Eur Radiol. 2006 Mar;16(3):661-9. doi: 10.1007/s00330-005-0029-9. Epub 2005 Oct 14. Eur Radiol. 2006. PMID: 16228211
-
Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study.PLoS One. 2020 Sep 28;15(9):e0239733. doi: 10.1371/journal.pone.0239733. eCollection 2020. PLoS One. 2020. PMID: 32986758 Free PMC article. Clinical Trial.
-
Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy.J Hepatocell Carcinoma. 2015 Sep 2;2:123-9. doi: 10.2147/JHC.S44380. eCollection 2015. J Hepatocell Carcinoma. 2015. PMID: 27508201 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical